1
|
Ngan Kee N, Foster E, Marquina C, Tan A, Pang SST, O'Brien TJ, Kwan P, Jackson GD, Chen Z, Ademi Z. Systematic Review of Cost-Effectiveness Analysis for Surgical and Neurostimulation Treatments for Drug-Resistant Epilepsy in Adults. Neurology 2023; 100:e1866-e1877. [PMID: 36927880 PMCID: PMC10159768 DOI: 10.1212/wnl.0000000000207137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2022] [Accepted: 01/18/2023] [Indexed: 03/18/2023] Open
Abstract
BACKGROUND AND OBJECTIVES Surgical and neurostimulator treatments are effective for reducing seizure burden in selected individuals living with drug-resistant epilepsy (DRE). We aimed to determine the presence and key model determinants for cost-effectiveness of these interventions, compared with medical management alone, to assist with decisions about resource allocation. METHODS A systematic literature search was conducted on June 1, 2022, using MEDLINE, EMBASE, the NHS Economic Evaluation Database, and the Cost-Effectiveness Analysis database. Included studies were economic evaluations in adult DRE cohorts, comparing surgical and neurostimulator treatments (vagus nerve stimulation [VNS], responsive neurostimulation [RNS], and deep brain stimulation [DBS]) vs medical management alone and reporting cost-benefit analysis, cost-utility, or cost-effectiveness. Exclusion criteria were studies with pediatric cohorts and those published in a language other than English. Three independent reviewers screened, extracted, and assessed data against the Consolidated Health Economic Evaluation Reporting Standards checklist, and a fourth reviewer adjudicated discrepancies. RESULTS Ten studies met inclusion criteria. Seven studies evaluated epilepsy surgery, and 3 evaluated neurostimulation treatments. All relevant studies established that epilepsy surgery is a cost-effective intervention compared with medical management alone, for quality-adjusted life-years and seizure freedom at 2 and 5 years. All relevant studies found neurostimulator treatments to be potentially cost-effective. The incremental cost-effectiveness ratio (ICER), with lower ICER indicating greater cost-effectiveness, was reported for 9 studies and varied between GBP £3,013 and US $61,333. Cost adaptation revealed ICERs from US $170 to US $121,726. Key model determinants included, but were not limited to, improved surgical outcomes and quality of life, reduced surgical and presurgical evaluation costs, higher rates of surgical eligibility after referral and evaluation, epilepsy subtype, less expensive neurostimulator devices with improved longevity, and cost analysis strategy used in the analysis. DISCUSSION There is consistent evidence that epilepsy surgery is a cost-effective treatment of eligible candidates with DRE. Limited evidence suggests that VNS, RNS, and DBS may be cost-effective therapies for DRE, although more health economic evaluations alongside prospective clinical trials are needed to validate these findings. STUDY REGISTRATION INFORMATION PROSPERO CRD42021278436.
Collapse
Affiliation(s)
- Nicholas Ngan Kee
- From the The Royal Melbourne Hospital (N.N.K., T.J.O.B., P.K.), Parkville; Department of Neuroscience (E.F., T.J.O.B., P.K., Z.C., Z.A.), Central Clinical School, Monash University, Melbourne; Department of Neurology (E.F., T.J.O.B., P.K., Z.C.), Alfred Health, Melbourne; School of Public Health and Preventive Medicine (C.M., P.K., Z.C., Z.A.), Monash University, Melbourne; Centre for Medicine Use and Safety (C.M., Z.A.), Monash University, Parkville; Faculty of Medicine, Nursing and Health Sciences (A.T., S.S.T.P.), Monash University, Clayton; Department of Medicine (T.J.O.B., P.K., G.D.J., Z.C.), The University of Melbourne, Parkville; Monash Institute of Medical Engineering (P.K.), Monash University, Clayton; Florey Institute of Neuroscience and Mental Health (G.D.J.), Melbourne; and Department of Neurology (G.D.J.), Austin Hospital, Heidelberg, Australia
| | - Emma Foster
- From the The Royal Melbourne Hospital (N.N.K., T.J.O.B., P.K.), Parkville; Department of Neuroscience (E.F., T.J.O.B., P.K., Z.C., Z.A.), Central Clinical School, Monash University, Melbourne; Department of Neurology (E.F., T.J.O.B., P.K., Z.C.), Alfred Health, Melbourne; School of Public Health and Preventive Medicine (C.M., P.K., Z.C., Z.A.), Monash University, Melbourne; Centre for Medicine Use and Safety (C.M., Z.A.), Monash University, Parkville; Faculty of Medicine, Nursing and Health Sciences (A.T., S.S.T.P.), Monash University, Clayton; Department of Medicine (T.J.O.B., P.K., G.D.J., Z.C.), The University of Melbourne, Parkville; Monash Institute of Medical Engineering (P.K.), Monash University, Clayton; Florey Institute of Neuroscience and Mental Health (G.D.J.), Melbourne; and Department of Neurology (G.D.J.), Austin Hospital, Heidelberg, Australia
| | - Clara Marquina
- From the The Royal Melbourne Hospital (N.N.K., T.J.O.B., P.K.), Parkville; Department of Neuroscience (E.F., T.J.O.B., P.K., Z.C., Z.A.), Central Clinical School, Monash University, Melbourne; Department of Neurology (E.F., T.J.O.B., P.K., Z.C.), Alfred Health, Melbourne; School of Public Health and Preventive Medicine (C.M., P.K., Z.C., Z.A.), Monash University, Melbourne; Centre for Medicine Use and Safety (C.M., Z.A.), Monash University, Parkville; Faculty of Medicine, Nursing and Health Sciences (A.T., S.S.T.P.), Monash University, Clayton; Department of Medicine (T.J.O.B., P.K., G.D.J., Z.C.), The University of Melbourne, Parkville; Monash Institute of Medical Engineering (P.K.), Monash University, Clayton; Florey Institute of Neuroscience and Mental Health (G.D.J.), Melbourne; and Department of Neurology (G.D.J.), Austin Hospital, Heidelberg, Australia
| | - Andy Tan
- From the The Royal Melbourne Hospital (N.N.K., T.J.O.B., P.K.), Parkville; Department of Neuroscience (E.F., T.J.O.B., P.K., Z.C., Z.A.), Central Clinical School, Monash University, Melbourne; Department of Neurology (E.F., T.J.O.B., P.K., Z.C.), Alfred Health, Melbourne; School of Public Health and Preventive Medicine (C.M., P.K., Z.C., Z.A.), Monash University, Melbourne; Centre for Medicine Use and Safety (C.M., Z.A.), Monash University, Parkville; Faculty of Medicine, Nursing and Health Sciences (A.T., S.S.T.P.), Monash University, Clayton; Department of Medicine (T.J.O.B., P.K., G.D.J., Z.C.), The University of Melbourne, Parkville; Monash Institute of Medical Engineering (P.K.), Monash University, Clayton; Florey Institute of Neuroscience and Mental Health (G.D.J.), Melbourne; and Department of Neurology (G.D.J.), Austin Hospital, Heidelberg, Australia
| | - Samantha S T Pang
- From the The Royal Melbourne Hospital (N.N.K., T.J.O.B., P.K.), Parkville; Department of Neuroscience (E.F., T.J.O.B., P.K., Z.C., Z.A.), Central Clinical School, Monash University, Melbourne; Department of Neurology (E.F., T.J.O.B., P.K., Z.C.), Alfred Health, Melbourne; School of Public Health and Preventive Medicine (C.M., P.K., Z.C., Z.A.), Monash University, Melbourne; Centre for Medicine Use and Safety (C.M., Z.A.), Monash University, Parkville; Faculty of Medicine, Nursing and Health Sciences (A.T., S.S.T.P.), Monash University, Clayton; Department of Medicine (T.J.O.B., P.K., G.D.J., Z.C.), The University of Melbourne, Parkville; Monash Institute of Medical Engineering (P.K.), Monash University, Clayton; Florey Institute of Neuroscience and Mental Health (G.D.J.), Melbourne; and Department of Neurology (G.D.J.), Austin Hospital, Heidelberg, Australia
| | - Terence J O'Brien
- From the The Royal Melbourne Hospital (N.N.K., T.J.O.B., P.K.), Parkville; Department of Neuroscience (E.F., T.J.O.B., P.K., Z.C., Z.A.), Central Clinical School, Monash University, Melbourne; Department of Neurology (E.F., T.J.O.B., P.K., Z.C.), Alfred Health, Melbourne; School of Public Health and Preventive Medicine (C.M., P.K., Z.C., Z.A.), Monash University, Melbourne; Centre for Medicine Use and Safety (C.M., Z.A.), Monash University, Parkville; Faculty of Medicine, Nursing and Health Sciences (A.T., S.S.T.P.), Monash University, Clayton; Department of Medicine (T.J.O.B., P.K., G.D.J., Z.C.), The University of Melbourne, Parkville; Monash Institute of Medical Engineering (P.K.), Monash University, Clayton; Florey Institute of Neuroscience and Mental Health (G.D.J.), Melbourne; and Department of Neurology (G.D.J.), Austin Hospital, Heidelberg, Australia
| | - Patrick Kwan
- From the The Royal Melbourne Hospital (N.N.K., T.J.O.B., P.K.), Parkville; Department of Neuroscience (E.F., T.J.O.B., P.K., Z.C., Z.A.), Central Clinical School, Monash University, Melbourne; Department of Neurology (E.F., T.J.O.B., P.K., Z.C.), Alfred Health, Melbourne; School of Public Health and Preventive Medicine (C.M., P.K., Z.C., Z.A.), Monash University, Melbourne; Centre for Medicine Use and Safety (C.M., Z.A.), Monash University, Parkville; Faculty of Medicine, Nursing and Health Sciences (A.T., S.S.T.P.), Monash University, Clayton; Department of Medicine (T.J.O.B., P.K., G.D.J., Z.C.), The University of Melbourne, Parkville; Monash Institute of Medical Engineering (P.K.), Monash University, Clayton; Florey Institute of Neuroscience and Mental Health (G.D.J.), Melbourne; and Department of Neurology (G.D.J.), Austin Hospital, Heidelberg, Australia
| | - Graeme D Jackson
- From the The Royal Melbourne Hospital (N.N.K., T.J.O.B., P.K.), Parkville; Department of Neuroscience (E.F., T.J.O.B., P.K., Z.C., Z.A.), Central Clinical School, Monash University, Melbourne; Department of Neurology (E.F., T.J.O.B., P.K., Z.C.), Alfred Health, Melbourne; School of Public Health and Preventive Medicine (C.M., P.K., Z.C., Z.A.), Monash University, Melbourne; Centre for Medicine Use and Safety (C.M., Z.A.), Monash University, Parkville; Faculty of Medicine, Nursing and Health Sciences (A.T., S.S.T.P.), Monash University, Clayton; Department of Medicine (T.J.O.B., P.K., G.D.J., Z.C.), The University of Melbourne, Parkville; Monash Institute of Medical Engineering (P.K.), Monash University, Clayton; Florey Institute of Neuroscience and Mental Health (G.D.J.), Melbourne; and Department of Neurology (G.D.J.), Austin Hospital, Heidelberg, Australia
| | - Zhibin Chen
- From the The Royal Melbourne Hospital (N.N.K., T.J.O.B., P.K.), Parkville; Department of Neuroscience (E.F., T.J.O.B., P.K., Z.C., Z.A.), Central Clinical School, Monash University, Melbourne; Department of Neurology (E.F., T.J.O.B., P.K., Z.C.), Alfred Health, Melbourne; School of Public Health and Preventive Medicine (C.M., P.K., Z.C., Z.A.), Monash University, Melbourne; Centre for Medicine Use and Safety (C.M., Z.A.), Monash University, Parkville; Faculty of Medicine, Nursing and Health Sciences (A.T., S.S.T.P.), Monash University, Clayton; Department of Medicine (T.J.O.B., P.K., G.D.J., Z.C.), The University of Melbourne, Parkville; Monash Institute of Medical Engineering (P.K.), Monash University, Clayton; Florey Institute of Neuroscience and Mental Health (G.D.J.), Melbourne; and Department of Neurology (G.D.J.), Austin Hospital, Heidelberg, Australia.
| | - Zanfina Ademi
- From the The Royal Melbourne Hospital (N.N.K., T.J.O.B., P.K.), Parkville; Department of Neuroscience (E.F., T.J.O.B., P.K., Z.C., Z.A.), Central Clinical School, Monash University, Melbourne; Department of Neurology (E.F., T.J.O.B., P.K., Z.C.), Alfred Health, Melbourne; School of Public Health and Preventive Medicine (C.M., P.K., Z.C., Z.A.), Monash University, Melbourne; Centre for Medicine Use and Safety (C.M., Z.A.), Monash University, Parkville; Faculty of Medicine, Nursing and Health Sciences (A.T., S.S.T.P.), Monash University, Clayton; Department of Medicine (T.J.O.B., P.K., G.D.J., Z.C.), The University of Melbourne, Parkville; Monash Institute of Medical Engineering (P.K.), Monash University, Clayton; Florey Institute of Neuroscience and Mental Health (G.D.J.), Melbourne; and Department of Neurology (G.D.J.), Austin Hospital, Heidelberg, Australia.
| |
Collapse
|